Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
PTCT Stock Chart & Stats
$64.39
>-$0.01(-0.02%)
At close: 4:00 PM EST
$64.39
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$35.95 - $87.50
Previous CloseN/A
Volume146.45K
Average Volume (3M)1.07M
Market Cap
$5.33B
Enterprise Value$4.88B
Total Cash (Recent Filing)$1.95B
Total Debt (Recent Filing)$492.28M
Price to Earnings (P/E)8.3
Beta1.25
Next Earnings
Apr 23, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding82,774,730
10 Day Avg. Volume1,143,608
30 Day Avg. Volume1,070,629
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-29.43
Price to Sales (P/S)3.49
P/FCF Ratio8.60
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue2.82
Enterprise Value/Gross Profit3.10
Enterprise Value/Ebitda5.50
Forecast
1Y Price Target
$91.89Price Target Upside42.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.74
Revenue Forecast (FY)$969.28M
Bulls Say, Bears Say
Bulls Say
International Expansion And Pricing StrategyManagement intends to sequence international launches and maintain a narrow pricing corridor, which could expand revenue in markets like Japan and Brazil while protecting pricing consistency.
Pipeline And Regulatory PathwaysRegulatory alignment on a Phase 3 design for votoplam and an open‑label pathway for vatiquinone in another indication create clearer approval routes that could add meaningful revenue beyond the lead product.
Sephience Commercial AdoptionAnalyst notes Sephience has produced a strong launch with broad uptake across patient groups, high refill rates and low discontinuation, indicating durable upside for product revenue.
Bears Say
DMD Franchise ErosionExpected erosion of the Duchenne muscular dystrophy franchise from generic competition and uneven translarna uptake poses a significant downside risk to future revenue.
Elevated Operating CostsManagement guidance for sustained elevated research and selling expenses, excluding stock-based compensation, could pressure margins and delay progress toward cash-flow breakeven despite commercial gains.
Lost US Opportunity And Removed RoyaltyWithdrawal of the Translarna US application and monetization of the Evrysdi royalty stream remove potential US sales and future royalty income from valuation models, reducing upside for revenue projections.
PTC Therapeutics News
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $35.95 and its highest was $87.50 in the past 12 months.
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $5.33B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Apr 23, 2026 which is in 49 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Feb 19, 2026. The company reported -$1.67 earnings per share for the quarter, missing the consensus estimate of $0.103 by -$1.773.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -0.44.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 82,774,730 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$1.67 in its last earnings report, missing expectations of $0.103. Following the earnings report the stock price went up 1.087%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Currently, no hedge funds are holding shares in PTCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PTC Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$91.89 (42.71% Upside)
$91.89 (42.71% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 477.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
69.58%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
PTCT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and financial story driven by Sephience's rapid global approvals and impressive early launch metrics, revenue outperformance for 2025, a strengthened cash position (~$1.95B), disciplined OpEx, and clear R&D progress (notably votoplam Phase III alignment). Offsetting items include regulatory setbacks for vatiquinone requiring additional study, reduced future Evrysdi royalty exposure following a royalty sale, pressure on the DMD franchise from generics, and some near-term expense increases and geographic concentration of Sephience revenue. Overall, the positives (robust launch, revenue beat, cash runway, and advancing pipeline programs) materially outweigh the negatives, though several development and commercialization risks remain.View all PTCT earnings summariesPTCT Stock 12 Month Forecast
Average Price Target
$91.89
▲(42.71% Upside)
Technical Analysis
Ownership Overview
1.59% Insiders
25.01% Mutual Funds
4.42% Other Institutional Investors
41.28% Public Companies and
Individual Investors